Strategies for treating chronic HCV infection in patients with cirrhosis: Latest evidence and clinical outcomes

Therapeutic Advances in Chronic Disease

Volumn 6, Issue 6, 2015, Pages 314-327

  Wilder, Julius M ^a   Muir, Andrew J ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Decompensated cirrhosis; Direct acting antivirals; Hepatitis C; Interferon free regimen

Indexed keywords

ASUNAPREVIR; BECLABUVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; ELBASVIR; GRAZOPREVIR; GS 9857; INTERFERON; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; TELAPREVIR; UNCLASSIFIED DRUG; VELPATASVIR;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; FIBROSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CIRRHOSIS; MUTATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

EID: 84945183985     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622315603642     Document Type: Review

References (50)

1. AASLD/IDSA/IAS-USA (2015) Recommendations for testing, managing, and treating hepatitis C. In: AASLD / IDSA (ed.), HCV Guidelines, Vol. 2015, Online Guidelines: http://www.hcvguidelines.org/
2. AbbVie (2014) Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), package insert. North Chicago, IL: AbbVie Inc.
3. Afdhal N. Reddy K. Nelson D. Lawitz E. Gordon S. Schiff E. et al. (2014 a) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483–1493.
4. Afdhal N. Zeuzem S. Kwo P. Chojkier M. Gitlin N. Puoti M. et al. (2014 b) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370: 1889–1898.
5. Backus L. Boothroyd D. Phillips B. Belperio P. Halloran J. Mole L. (2011) A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 9: 509.e1–516.e1.
6. Bacon B. Gordon S. Lawitz E. Marcellin P. Vierling J. Zeuzem S. et al. (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364: 1207–1217.
7. Bourliere M. Bronowicki J. de Ledinghen V. Hezode C. Zoulim F. Mathurin P. et al. (2015) Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 15: 397–404.
8. Charlton M. Everson G. Flamm S. Kumar P. Landis C. Brown R. Jr et al. (2015) Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology doi:10.1053/j.gastro.2015.05.010.
9. Crippin J. McCashland T. Terrault N. Sheiner P. Charlton M. (2002) A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 8: 350–355.
10. Di Bisceglie A. (2000) Natural history of hepatitis C: its impact on clinical management. Hepatology 31: 1014–1018.
11. EASL (2015) EASL Recommendations on Treatment of Hepatitis C 2015 Summary. Vienna, Austria: EASL.
12. Everson G. Trotter J. Forman L. Kugelmas M. Halprin A. Fey B. et al. (2005) Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42: 255–262.
13. Foster G. McLauchlan J. Irving W. Cheung M. Hudson B. et al. (2015) UK Early Access Program. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5a inhibitors with / without ribavirin is effective in HCV genotypes 1 and 3. In: 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, 22–26 April.
14. Foster G. Pianko S. Cooper C. Brown A. Forton D. Nahass R. et al. (2015) Sofosbuvir plus Peg-IFN/RBV for 12 weeks vs sofosbuvir / RBV for 16 or 24 weeks in genotype 3 HCV-infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the Boson Study.J Hepatol 62: S259–S260.
15. Gane E. Hyland R. An D. Svarovskaia E. Pang P. Symonds W. et al. (2014) High efficacy of LDV / SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Final ID: LB-11. Boston, MA: AASLD.
16. Gane E. Hyland R. Ying Y. Svarovskaia E. Stamm L. Brainard D. et al. (2015) Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatmentnaive and DAA-experienced genotype 1 patients with and without cirrhosis. J Hepatol 62: S264.
17. Gilead Sciences (2013) Sovaldi® (sofosbuvir). Foster City, CA: Gilead Sciences, Inc.
18. Gilead Sciences (2015) Harvoni® (ledipasvir and sofosbuvir). Foster City, CA: Gilead Sciences, Inc.
19. Hezode C. Fontaine H. Dorival C. Larrey D. Zoulim F. Canva V. et al. (2013) Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890. J Hepatol 59: 434–441.
20. Jacobson I. Gordon S. Kowdley K. Yoshida E. Rodriguez-Torres M. Sulkowski M. et al. (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867–1877.
21. Jacobson I. McHutchison J. Dusheiko G. Di Bisceglie A. Reddy K. Bzowej N. et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405–2416.
22. Janssen Therapeutics (2013) OlysioTM (simeprevir). Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP.
23. Lavanchy D. (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17: 107–115.
24. Lawitz E. Gane E. (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 369: 678–679.
25. Lawitz A. Gane E. Pearlman B. Tam E. Ghesquiere W. Guyader D. et al. (2015 a) Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385: 1075–1086.
26. Lawitz B. Matusow G. Dejesus E. Yoshida E. Felizarta F. Ghalib R. et al. (2015 b) A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatmentnaïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2. J Hepatol 62: S264–S265.
27. Lawitz E. Poordad F. Brainard D. Hyland R. An D. Dvory-Sobol H. et al. (2015 c) Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 61: 769–775.
28. Lawitz E. Sulkowski M. Ghalib R. Rodriguez-Torres M. Younossi Z. Corregidor A. et al. (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the Cosmos randomised study. Lancet 384: 1756–1765.
29. Liaw Y. Sheen I. Lee C. Akarca U. Papatheodoridis G. Suet-Hing Wong F. et al. (2011) Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 53: 62–72.
30. McHutchison J. Lawitz E. Shiffman M. Muir A. Galler G. McCone J. et al. (2009) Peginterferon ALFA-2b or ALFA-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580–593.
31. Mohd Hanafiah K. Groeger J. Flaxman A. Wiersma S. (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57: 1333–1342.
32. Morgan R. Baack B. Smith B. Yartel A. Pitasi M. Falck-Ytter Y. (2013) Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158: 329–337.
33. Muir A. Poordad F. Lalezari J. Everson G. Dore G. Herring R. et al. (2015) Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 313: 1736–1744.
34. Naggie S. Cooper C. Saag M. Stamm L. Yang J. Pang P. et al. (2015) Ledipasvir / sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1. N Engl J Med 373: 705–713.
35. Nelson D. Cooper J. Lalezari J. Lawitz E. Pockros P. Freilich B. et al. (2014) All-oral 12-week combination treatment with daclatasvir and sofosbuvir in patients infected with HCV genotype 3: ALLY-3 phase 3 study. Hepatology 61 (4): 1127–1135.
36. Pianko S. Flamm S. Shiffman M. Kumar S. Strasser S. Dore G. et al. (2014) High efficacy of treatment with sofosbuvir + GS 5816 +/– ribavirin for 12 weeks in treatment-experienced patients with genotype 1 or 3 HCV infection. Hepatology 60 (4): S297A–S298A
37. Pockros P. Carithers R. Mantry P. Cohen E. Bennett M. Sulkowski M. et al. (2015) Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT 1 infection in patients with severe renal impairment or end-stage renal disease: the Ruby-1 study. J Hepatol 62: S257.
38. Poordad F. Hezode C. Trinh R. Kowdley K. Zeuzem S. Agarwal K. et al. (2014) ABT-450/R-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370: 1973–1982.
39. Poordad F. McCone J. Jr Bacon B. Bruno S. Manns M. Sulkowski M. et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195–1206.
40. Poordad F. Schiff E. Vierling J. Landis C. Fontana R. Yang R. et al. (2015) Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. J Hepatol 62: S261–S262.
41. Reddy K. Bourliere M. Sulkowski M. Omata M. Zeuzem S. Feld J. et al. (2015) Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62: 79–86.
42. Roth D. Nelson D. Bruchfeld A. Liapakis A. Silva M. Monsour H. Jr et al. (2015) C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment- experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. J Hepatol 62: S263–S264.
43. Sherman K. Flamm S. Afdhal N. Nelson D. Sulkowski M. Everson G. et al. (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365: 1014–1024.
44. van der Meer A. Veldt B. Feld J. Wedemeyer H. Dufour J. Lammert F. et al. (2012) Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308: 2584–2593.
45. Wilder J. Patel K. (2014) A review of the natural history of chronic hepatitis C infection. N Am J Med Sci 7: 1–7.
46. World Health Organization (2014) Hepatitis C key facts. In: WHO (ed.), WHO Fact Sheet No 164. Geneva: WHO.
47. Zeuzem S. Andreone P. Pol S. Lawitz E. Diago M. Roberts S. et al. (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417–2428.
48. Zeuzem A. Berg T. Gane E. Ferenci P. Foster G. Fried M. et al. (2014 a) Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 146: 430.e6–441.e6.
49. Zeuzem B. Dusheiko G. Salupere R. Mangia A. Flisiak R. Hyland R. et al. (2014 b) Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370: 1993–2001.
50. Zeuzem S. Ghalib R. Reddy K. Pockros P. Ben Ari Z. Zhao Y. et al. (2015) Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163: 1–13.